Business Context and Reporting Period
This Form 8-K filing by Gossamer Bio, Inc. (GOSS) is dated February 19, 2025. The report addresses a regulatory matter concerning the company's continued listing on the Nasdaq Global Select Market.
Key Financial Metrics
The filing does not provide specific financial data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on a corporate governance and listing status event.
Material Changes
The primary material change reported is the resolution of a compliance issue with Nasdaq Listing Rule 5450(a)(1). On February 19, 2025, the company received confirmation from Nasdaq that it has regained compliance with the minimum bid price requirement. This resolves a deficiency previously identified on September 11, 2024, where the company's common stock failed to maintain a minimum bid price of $1.00 for 30 consecutive business days.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on financial outlook, or discussion of new risks or contingencies beyond the resolution of the listing deficiency. The unusual item noted is the prior non-compliance with the minimum bid price rule, which is now closed.
Investor Verification Checklist
- Verify the current trading price of GOSS to ensure it remains above the $1.00 minimum bid price threshold.
- Confirm the status of the Nasdaq listing on the Nasdaq Global Select Market.
- Review the company's most recent 10-Q or 10-K for financial performance data, as this 8-K does not contain financial statements.